Emerging and Evolving Biomarkers: MGMT

Enroll

 

 

 

This content was created in 2020, but has been reviewed and approved by the Training & Education Committee as useful, accurate, and relevant. Please note that in the time since this material was posted, there may have been additional developments, advancements, and/or more current publications in this field.

 

AMP Education is constantly updating our educational offerings, and will remove or replace content that is no longer accurate. Please be sure to use the search function to find related or updated material available in our catalogue at educate.amp.org. The Training and Education Committee works with AMP Education Programs to bring you the most up-to-date and cutting-edge information on molecular pathology research, applications, and training.

 

This webinar does not contain continuing education credit (CME and CMLE) 

Speaker:

Tejus A. Bale, MD, PhD

Moderator:

Lauren Ritterhouse, MD, PhD

This webinar is a recorded presentation of a live broadcast and includes the presentation, handout, and the audience QA.

 

Description:

The O6-methylguanine-DNA methyl-transferase (MGMT) gene encodes a widely expressed DNA repair enzyme, which reverses the anti-tumor effects of alkylating agents. Silencing of the MGMT gene, via promoter methylation, has emerged as a biomarker of interest in glioma with regards to tumor prognostication and treatment selection. In the era of numerous biologically relevant glioma biomarkers, the relative significance of MGMT testing will be considered, as well as the technical considerations and constraints surrounding commonly utilized assays.

Learning Objectives:

  • Describe the function of O6-methylguanine-DNA methyl-transferase (MGMT) and the effects of gene promoter methylation.
  • Describe the clinical significance of MGMT promoter methylation with regards to glioma therapy and risk stratification. 
  • Discuss the commonly used technical approaches and platforms for molecular diagnostic testing for MGMT gene methylation. 
  • Outline the strengths and limitations of described testing approaches.
This webinar is part 1 of the Emerging and Evolving Biomarkers Series. 
This program has been supported through an educational grant from Bristol-Myers Squibb.

Recording Date: June 30, 2020
Duration: 1 hr
Level of Instruction: Basic
This webinar does not contain continuing education credit (CME and CMLE)

 

 

 

AMP is pleased to collaborate in the Immunotherapy Collaborative of Oncology Networked Communities, IC-ONC.  IC-ONC is a global information network in which multidisciplinary healthcare providers, responsible for treating patients with cancer, are connected via education.  

Please be sure to visit www.ic-onc.org to learn more about the collaborative and all it has to offer.

 

 

Note: Members of AMP can access many of the webinars at no cost or a deep discount. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

 

 

Enroll